RxDoctor Payments Data

Doreen Bett, DO

Nephrology · Lancaster, PANPI 1386770501

Payments from drug & device makers

$2,726in general payments, 2019–2025

Across 24 payments — averaging $113.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Quanta Dialysis Technologies Inc$2K
  • Amgen$184
  • Ardelyx, Inc.$143
  • Vifor Pharma, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$100
  • Akebia Therapeutics Inc$39
  • plus $136 from 7 others
$50,380in research payments, 2019–2025

Across 12 payments — averaging $4198.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Quanta Dialysis Technologies Inc$50K

What the payments were for

  • Consulting fees$2,00073%
  • Food & beverage$72327%
  • Education$20%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,726 in reported general payments places this provider in the 70th percentile of 586 nephrology providers in Pennsylvania.

See all nephrology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$237,742
Medicare patients
514
Services billed
1,673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl13$38,324
FarxigaDapagliflozin Propanediol26$33,043
JardianceEmpagliflozin20$28,223
Cinacalcet Hcl23$13,438
Sevelamer Carbonate34$6,188
Eplerenone24$3,203
Calcium Acetate66$3,033
Nifedipine ErNifedipine83$2,146
Losartan Potassium215$2,093
Hydralazine Hcl105$2,036
Carvedilol199$1,732
Torsemide94$1,551
Amlodipine Besylate278$1,522
Clonidine19$1,511
Doxazosin Mesylate73$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$20$33,04326 claims
Boehringer IngelheimJardiance$20$28,22320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 nephrology providers in Pennsylvania.

Other nephrology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →